X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (480020) 480020
Book Review (57423) 57423
Publication (52487) 52487
Newspaper Article (23322) 23322
Newsletter (7074) 7074
Book Chapter (3040) 3040
Conference Proceeding (1611) 1611
Dissertation (705) 705
Web Resource (553) 553
Trade Publication Article (499) 499
Magazine Article (256) 256
Book / eBook (142) 142
Government Document (104) 104
Reference (68) 68
Data Set (49) 49
Report (26) 26
Paper (18) 18
Streaming Video (14) 14
Journal / eJournal (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (388173) 388173
humans (237444) 237444
animals (215969) 215969
kinases (113608) 113608
phosphorylation (99891) 99891
mice (96931) 96931
biochemistry & molecular biology (85824) 85824
male (84899) 84899
cell biology (82542) 82542
oncology (82262) 82262
proteins (81931) 81931
signal transduction (76969) 76969
apoptosis (72447) 72447
female (70882) 70882
cancer (64995) 64995
rats (61141) 61141
expression (60428) 60428
activation (57242) 57242
research (53024) 53024
gene expression (49479) 49479
cell line, tumor (49082) 49082
cells, cultured (48450) 48450
analysis (37126) 37126
cell line (36843) 36843
pharmacology & pharmacy (36192) 36192
mutation (35200) 35200
protein kinases (35050) 35050
cells (34790) 34790
signal transduction - drug effects (34605) 34605
article (33915) 33915
physiological aspects (32655) 32655
research article (32469) 32469
enzyme inhibitors - pharmacology (32321) 32321
cell cycle (31769) 31769
neurosciences (31309) 31309
multidisciplinary sciences (30841) 30841
rodents (30156) 30156
medicine (28872) 28872
genetic aspects (28607) 28607
inhibition (28089) 28089
health aspects (27226) 27226
middle aged (26900) 26900
tumors (26824) 26824
apoptosis - drug effects (26406) 26406
physiology (26237) 26237
kinase (25653) 25653
gene-expression (25402) 25402
cell proliferation (25282) 25282
biology (24409) 24409
inflammation (23830) 23830
immunology (23501) 23501
adult (22973) 22973
science (22952) 22952
blotting, western (22894) 22894
oxidative stress (22590) 22590
dose-response relationship, drug (22255) 22255
protein kinase inhibitors - pharmacology (22233) 22233
growth (21570) 21570
care and treatment (21508) 21508
in-vitro (21459) 21459
aged (21361) 21361
metastasis (21014) 21014
rats, sprague-dawley (20754) 20754
protein-kinase-c (20730) 20730
studies (20576) 20576
cell proliferation - drug effects (20052) 20052
medicine, research & experimental (19792) 19792
protein binding (19633) 19633
abridged index medicus (19541) 19541
enzymes (19486) 19486
protein-kinase (19484) 19484
protein (19448) 19448
antineoplastic agents - pharmacology (19422) 19422
in-vivo (19378) 19378
biochemistry (19368) 19368
protein-serine-threonine kinases - metabolism (19359) 19359
signal transduction - physiology (19336) 19336
enzyme activation (19184) 19184
activated protein-kinase (19180) 19180
genes (18809) 18809
mice, inbred c57bl (18746) 18746
proliferation (18700) 18700
time factors (18548) 18548
biophysics (18175) 18175
cell growth (18122) 18122
molecular sequence data (17999) 17999
pathway (17973) 17973
hematology (17938) 17938
phosphorylation - drug effects (17863) 17863
nf-kappa-b (17783) 17783
chemotherapy (17353) 17353
transfection (17079) 17079
immunohistochemistry (17056) 17056
endocrinology & metabolism (16828) 16828
protein kinase c - metabolism (16472) 16472
breast cancer (16309) 16309
tumor cells, cultured (16046) 16046
amino acid sequence (15819) 15819
cancer therapies (15768) 15768
metabolism (15747) 15747
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Online Resources - Online (73) 73
Gerstein Science - Stacks (47) 47
Collection Dvlpm't (Acquisitions) - Vendor file (12) 12
UofT at Mississauga - Stacks (4) 4
Chemistry (A D Allen) - Stacks (3) 3
UofT at Scarborough - Stacks (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
Earth Sciences (Noranda) - Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (507537) 507537
Chinese (2411) 2411
Japanese (1051) 1051
French (1023) 1023
German (781) 781
Russian (551) 551
Korean (210) 210
Spanish (189) 189
Polish (168) 168
Portuguese (78) 78
Hungarian (76) 76
Czech (71) 71
Italian (39) 39
Turkish (35) 35
Dutch (32) 32
Ukrainian (27) 27
Danish (19) 19
Croatian (12) 12
Swedish (12) 12
Finnish (10) 10
Norwegian (10) 10
Slovak (9) 9
Bulgarian (4) 4
Hebrew (4) 4
Serbian (4) 4
Romanian (3) 3
Slovenian (3) 3
Afrikaans (1) 1
Malay (1) 1
Persian (1) 1
Urdu (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 07/2017, Volume 35, Issue 19, pp. 2193 - 2202
Purpose Data suggest that DNA damage by poly (ADP-ribose) polymerase inhibition and/or reduced vascular endothelial growth factor signaling by vascular... 
SENSITIVE OVARIAN-CANCER | MULTICENTER | ANTI-PD-1 | ONCOLOGY | ANTITUMOR-ACTIVITY | NIVOLUMAB | Piperazines - administration & dosage | Vascular Endothelial Growth Factor Receptor-1 - antagonists & inhibitors | Phthalazines - pharmacokinetics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Quinazolines - pharmacokinetics | Protein Kinase Inhibitors - adverse effects | Dose-Response Relationship, Drug | Genital Neoplasms, Female - drug therapy | Adult | Female | Quinazolines - administration & dosage | Piperazines - pharmacokinetics | Phthalazines - administration & dosage | Antibodies, Monoclonal - pharmacokinetics | Genital Neoplasms, Female - immunology | B7-H1 Antigen - immunology | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Genital Neoplasms, Female - metabolism | Protein Kinase Inhibitors - administration & dosage | B7-H1 Antigen - antagonists & inhibitors | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | B7-H1 Antigen - biosynthesis | Quinazolines - adverse effects | Aged | Genital Neoplasms, Female - pathology | Phthalazines - adverse effects | Lymphocytes, Tumor-Infiltrating - immunology | Index Medicus | Phase I and Clinical Pharmacology | Combined Modality | Breast Cancer | ORIGINAL REPORTS
Journal Article
2012, Methods in molecular biology, ISBN 1617793361, Volume 795., xi, 256
Book
2009, 1. Aufl., Wiley Series in Drug Discovery and Development, ISBN 0470278293, Volume 10, xv, 510
A comprehensive resource on case studies of marketed kinase drugs and promising drug trialsSince the discovery of protein kinase activity in 1954, the field of... 
Protein Kinase Inhibitors | Inhibitors | drug therapy | pharmacology | metabolism | Antineoplastic agents | Protein kinases | Drug Discovery | Neoplasms | Therapeutic use | Protein kinases–Inhibitors–Therapeutic use | Medical | Pharmacology
Book
Journal of Clinical Investigation, ISSN 0021-9738, 05/2009, Volume 119, Issue 5, pp. 1109 - 1123
Imatinib mesylate (IM), a potent inhibitor of the BCR/ABL tyrosine kinase, has become standard first-line therapy for patients with chronic myeloid leukemia... 
CHRONIC MYELOGENOUS LEUKEMIA | MEDICINE, RESEARCH & EXPERIMENTAL | MALIGNANT GLIOMA-CELLS | BLAST CRISIS | CLINICAL RESISTANCE | BCR-ABL MUTATIONS | ENDOPLASMIC-RETICULUM | CYTOCHROME-C RELEASE | CASPASE ACTIVATION | IMATINIB RESISTANCE | CHRONIC MYELOID-LEUKEMIA | Transcription Factor CHOP - genetics | Neoplastic Stem Cells - cytology | Gene Expression - drug effects | Calcium - metabolism | Gene Expression - genetics | Microtubule-Associated Proteins - metabolism | Neoplastic Stem Cells - drug effects | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Endoplasmic Reticulum - metabolism | Antineoplastic Agents - therapeutic use | Autophagy - physiology | Thiazoles - therapeutic use | Autophagy - drug effects | Chloroquine - pharmacology | Neoplastic Stem Cells - metabolism | RNA Interference | Endoplasmic Reticulum - drug effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Macrolides - pharmacology | Antineoplastic Agents - pharmacology | Cell Death - drug effects | Dasatinib | Chloroquine - therapeutic use | Piperazines - therapeutic use | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Mice, Inbred C3H | Xenograft Model Antitumor Assays | Fusion Proteins, bcr-abl - genetics | Animals | Cell Death - physiology | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Cell Line, Tumor | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Mice | Protein Kinase Inhibitors - pharmacology | Thiazoles - pharmacology | Benzamides | Macrolides - therapeutic use | Protein-Tyrosine Kinases - antagonists & inhibitors | Causes of | Physiological aspects | Genetic aspects | Chronic myeloid leukemia | Research | Drug therapy | Phagocytosis | Index Medicus | Abridged Index Medicus
Journal Article
Chemical Biology & Drug Design, ISSN 1747-0277, 01/2011, Volume 77, Issue 1, pp. 1 - 11
The BCR‐ABL inhibitor imatinib has revolutionized the treatment of chronic myeloid leukemia. However, drug resistance caused by kinase domain mutations has... 
kinase | ponatinib | AP24534 | drug discovery | X‐ray crystallography | structure‐based drug design | X-ray crystallography | Structure-based drug design | Drug discovery | Ponatinib | Kinase | structure-based drug design | C-ABL | CRYSTAL-STRUCTURE | BIOCHEMISTRY & MOLECULAR BIOLOGY | BMS-354825 | DOMAIN MUTATIONS | CANCER | CHRONIC MYELOID-LEUKEMIA | STRATEGIES | THERAPY | IMATINIB | T315I MUTANT | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Crystallography, X-Ray | Piperazines - chemistry | Structure-Activity Relationship | Pyridazines - pharmacology | Pyridazines - chemical synthesis | Pyrimidines - chemistry | Protein Kinase Inhibitors - chemistry | Protein Binding - drug effects | Imidazoles - chemical synthesis | Imidazoles - therapeutic use | Pyridazines - therapeutic use | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Imidazoles - pharmacology | Piperazines - therapeutic use | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Drug Resistance, Neoplasm - genetics | Fusion Proteins, bcr-abl - genetics | Animals | Mutation - drug effects | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Cell Line, Tumor | Mice | Protein Kinase Inhibitors - pharmacology | Benzamides | Fluoroimmunoassay | Fusion Proteins, bcr-abl - metabolism | Drug Resistance, Neoplasm - drug effects | Drug resistance | Analysis | Leukemia | Index Medicus | STRUCTURE-ACTIVITY RELATIONSHIPS | MUTANTS | BASIC BIOLOGICAL SCIENCES | ENZYME INHIBITORS | TYROSINE | GENE MUTATIONS | PHOSPHOTRANSFERASES | MYELOID LEUKEMIA | MUTATIONS | ANTINEOPLASTIC DRUGS | 60 APPLIED LIFE SCIENCES | RESIDUES
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2015, Volume 372, Issue 18, pp. 1689 - 1699
AZD9291, an irreversible inhibitor of epidermal growth factor receptor, was associated with tumor responses in the majority of patients with advanced... 
MEDICINE, GENERAL & INTERNAL | GEFITINIB | PLACEBO | PHASE-III | ACQUIRED-RESISTANCE | OPEN-LABEL | MUTATIONS | AFATINIB | IRREVERSIBLE EGFR | CHEMOTHERAPY | ERLOTINIB | Lung Neoplasms - drug therapy | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Acrylamides - pharmacokinetics | Dose-Response Relationship, Drug | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Aniline Compounds - administration & dosage | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | ErbB Receptors - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - genetics | Aniline Compounds - pharmacokinetics | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Acrylamides - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Aniline Compounds - adverse effects | Acrylamides - adverse effects | Clinical trials | Care and treatment | Usage | Diagnosis | Lung cancer, Non-small cell | Patient outcomes | Tyrosine | Appetite | Inhibitor drugs | Epidermal growth factor receptors | Lung | Lung cancer | Diarrhea | Nausea | Drug resistance | Kinases | Patients | Epidermal growth factor | Pharmacokinetics | Protein-tyrosine kinase | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 11/2006, Volume 49, Issue 23, pp. 6819 - 6832
Journal Article
2012, 1. Aufl., Current topics in microbiology and immunology, ISBN 3642282954, Volume 355., x, 234
Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function,... 
Chemotherapy | Antineoplastic Protocols | Cancer | Clinical & internal medicine | Protein kinases | Inhibitors
Book
PLoS ONE, ISSN 1932-6203, 02/2017, Volume 12, Issue 2, pp. e0171221 - e0171221
Journal Article
International Journal of Cancer, ISSN 0020-7136, 11/2013, Volume 133, Issue 9, pp. 2089 - 2101
The RAS/RAF/MEK/MAPK and the PTEN/PI3K/AKT/mTOR pathways are key regulators of proliferation and survival in human cancer cells. Selective inhibitors of... 
lung cancer | colorectal cancer | combination of molecular targeted therapies | MEK inhibitors | SIGNALING PATHWAYS | ACTIVATION | RAS | AZD6244 | ARRY-142886 | IDENTIFICATION | PI3K | ONCOLOGY | SELUMETINIB | KRAS | TUMOR-GROWTH | Lung Neoplasms - drug therapy | Oligonucleotide Array Sequence Analysis | TOR Serine-Threonine Kinases - metabolism | Apoptosis - drug effects | Phosphatidylinositol 3-Kinase - antagonists & inhibitors | Humans | Lung Neoplasms - metabolism | Lung Neoplasms - pathology | Gene Expression Profiling | TOR Serine-Threonine Kinases - antagonists & inhibitors | Colorectal Neoplasms - drug therapy | Biomarkers, Tumor - metabolism | Female | Tumor Cells, Cultured | Proto-Oncogene Proteins c-akt - metabolism | Phosphatidylinositol 3-Kinase - metabolism | Colorectal Neoplasms - metabolism | MAP Kinase Kinase 1 - antagonists & inhibitors | PTEN Phosphohydrolase - metabolism | MAP Kinase Kinase 1 - metabolism | MAP Kinase Kinase 2 - metabolism | Blotting, Western | Xenograft Model Antitumor Assays | Animals | Signal Transduction - drug effects | MAP Kinase Kinase 2 - antagonists & inhibitors | Biomarkers, Tumor - genetics | Cell Proliferation - drug effects | Mice | Mice, Inbred BALB C | Phenylurea Compounds - pharmacology | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Cell Cycle - drug effects | Colorectal Neoplasms - pathology | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Drug Resistance, Neoplasm - drug effects | Colorectal cancer | Tumors | Chemotherapy | Pharmacology | Kinases | Lung cancer | Index Medicus
Journal Article